@misc{10481/107802,
year = {2014},
month = {6},
url = {https://hdl.handle.net/10481/107802},
abstract = {The present invention refers to a method of predicting or prognosticating the response of a human subject to immunotherapy (from hereinafter method of the invention), wherein the subject is suffering from a cancer disease, and wherein the method comprises using, as an indicator, expression levels of p2-microglobulin from the tumour cells of a biological sample of the subject; wherein the result is indicative of a negative response if the expression levels of β2-microglobulin are under-expressed in comparison to a reference sample and/or a positive control. In a preferred embodiment of the invention, the expression levels are determined after said subject has been treated with immunotherapy.},
organization = {Servicio Andaluz de salud},
organization = {Fundacion pública andaluza para la investigacion biosanitaria de andalucia oriental},
organization = {Universidad de Granada},
publisher = {WIPO (PCT)},
keywords = {beta2-microglobulin},
keywords = {B2m},
keywords = {Immunotherapy},
keywords = {Biomarker},
keywords = {Cancer},
keywords = {Gene therapy},
title = {Expression of beta2-microglobulin as a prognostic marker for tumour immune escape and resistance to cancer immunotherapy and a diagnostic biomarker for patient selection for specific gene therapy},
author = {Carretero Coca, Rafael},
}